China SXT Pharmaceuticals, Inc. (SXTC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SXTC Profit Margin, ROE & Profitability Analysis
SXTC vs Healthcare Sector: How China SXT Pharmaceuticals, Inc. Compares
How China SXT Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is China SXT Pharmaceuticals, Inc. Stock Overvalued? SXTC Valuation Analysis 2026
Based on fundamental analysis, China SXT Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
China SXT Pharmaceuticals, Inc. Balance Sheet: SXTC Debt, Cash & Liquidity
SXTC Revenue Growth, EPS Growth & YoY Performance
SXTC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for China SXT Pharmaceuticals, Inc. (CIK: 0001723980)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SXTC
What is the AI rating for SXTC?
China SXT Pharmaceuticals, Inc. (SXTC) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SXTC's key strengths?
Claude: Analysis in progress.
What are the risks of investing in SXTC?
Claude: Analysis in progress.
What is SXTC's revenue and growth?
China SXT Pharmaceuticals, Inc. reported revenue of N/A.
Does SXTC pay dividends?
China SXT Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find SXTC SEC filings?
Official SEC filings for China SXT Pharmaceuticals, Inc. (CIK: 0001723980) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SXTC's EPS?
China SXT Pharmaceuticals, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SXTC's fundamental grade?
Based on our AI fundamental analysis in May 2026, China SXT Pharmaceuticals, Inc. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SXTC stock overvalued or undervalued?
Valuation metrics for SXTC: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SXTC's AI grade for 2026?
Our dual AI analysis gives China SXT Pharmaceuticals, Inc. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SXTC's free cash flow?
China SXT Pharmaceuticals, Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does SXTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).